MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
13.63
-0.32
-2.29%
Opening 11:43 03/27 EDT
OPEN
13.80
PREV CLOSE
13.95
HIGH
13.80
LOW
13.49
VOLUME
149.32K
TURNOVER
--
52 WEEK HIGH
20.72
52 WEEK LOW
3.390
MARKET CAP
310.61M
P/E (TTM)
-2.3347
1D
5D
1M
3M
1Y
5Y
1D
Avalo Therapeutics Price Target Raised to $40.00/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Avalo Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $40
Benzinga · 2d ago
Avalo Therapeutics price target raised to $40 from $25 at H.C. Wainwright
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Reuters · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 3d ago
Analysts’ Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), Biohaven Ltd. (BHVN)
TipRanks · 3d ago
Avalo Therapeutics Price Target Maintained With a $40.00/Share by BTIG
Dow Jones · 3d ago
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.